Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707434 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring in Critically Ill
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00707434: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00707434 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00707434, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if The Guardian® blood-sugar monitoring device can be used reliably in patients with high blood sugar who are receiving care in the ICU. Researchers will compare blood-sugar measurements from the study device with blood-sugar measurements from the standard "fingerstick" method of blood-sugar testing. This is being done to see if the new device can accurately measure blood sugar.
Interventions
- DEVICE Guardian® blood-sugar monitoring device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-06 |
| Est. Completion | 2016-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00707434
The ClinicalTrials.gov registry entry for NCT00707434 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guardian® blood-sugar monitoring device is the first listed.
NCT00707434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00707434 about?
NCT00707434 is a clinical study titled "Continuous Glucose Monitoring in Critically Ill". The goal of this clinical research study is to learn if The Guardian® blood-sugar monitoring device can be used reliably in patients with high blood sugar who are receiving care in the ICU. Researchers will compare blood-sugar measurements from the study device with blood-sugar measurements from the...
What is the current status of trial NCT00707434?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2008-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT00707434?
The interventions under investigation include: Guardian® blood-sugar monitoring device (DEVICE).
Who is sponsoring clinical trial NCT00707434?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.